中国结合医学杂志（英文版）Chinese Journal of Integrative Medicine

Author Name	Affiliation	E-mail
Jae-Woo Park , Jeungwon Yoon , Chong-Kwan Cho
Hwa-Seung Yoo	East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University, 1136 Dunsandong Seogu Daejeon 302-122, Soul, Korea	altyhs@dju1kr

Hits: 1185

Download times: 893

Abstract:

Objective: To evaluate the efficacy of HangAm-Plus (HAP) on stage Ⅳ metastatic gastric cancer by analyzing the treated patients' overall survival outcome. Methods: Following the study eligibility, overall survival and one year survival rate of 44 stage Ⅳ metastatic gastric cancer patients who visited East-West Cancer Center (EWCC) were analyzed. The study consisted of two arms: HAP treatment only (n=18) and combined treatment of concurrent conventional chemotherapy and HAP (n=26). Patient characteristics by gender, age, surgical intervention, Eastern Cooperative Oncology Group (ECOG) score, treatment duration (< 4 weeks or 4 weeks), and lines of the chemotherapy received were assessed. Treatment related side effects were also assessed. Results: The median survival of combined group was longer (10.0 months) than that of HAP group (5.1 months). One-year survival rate of combined treatment group and HAP group was 38.5%±9.5% and 33.3%±11.1%, respectively (P>0.05). One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7% and 8.3%±8.0%, respectively (P=0.001). Conclusions: The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stage Ⅳ metastatic gastric cancer treated with conventional chemotherapy. Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.